That puts a lot of pressure on the makeup of trial assessment—as well as understanding the maximum potential of each preventive candidate.
In an interview with Contagion, William Schaffner, MD, professor of Preventive Medicine and Medicine at the Vanderbilt University Medical Center, discussed the variability of marketed vaccines and how expectations differentiate for each disease. For example, he noted, the difference in modern protection from shingles versus influenza is significant.
And what could be hoped for in a COVID-19 vaccine?
“We would hope for something that is over 80% effective,” he said. “We have to, I think, in the 21st century, have a product that is at least 80% effective. They would hope for more, of course.”
Schaffner also discussed the stratified assessment of vaccine candidates across age groups, and the potential need of booster administrations and eventual clinical follow-up with a COVID-19 vaccine.
To stay informed on the latest in infectious disease news and developments, please sign upfor our weekly newsletter.
Is there a cure? How long until we find it? And will it work for the majority of people living with HIV?
Contagion® is a fully integrated news resource covering all areas of infectious disease. Through our website, quarterly journal, email newsletters, social media outlets, and Outbreak Monitor we provide practitioners and specialists with disease-specific information designed to improve patient outcomes and assist with the identification, diagnosis, treatment, and prevention of infectious diseases. Our mission is to assure that the healthcare community and public have the knowledge to make more informed choices and have a positive impact on patient outcomes.
2 Clarke Drive
Cranbury, NJ 08512